NASDAQ:ESPR - Esperion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $52.89
  • Forecasted Upside: 93.10 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$27.39
▼ -0.29 (-1.05%)
1 month | 3 months | 12 months
Get New Esperion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESPR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$52.89
▲ +93.10% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $52.89, with a high forecast of $134.00 and a low forecast of $24.00. The average price target represents a 93.10% upside from the last price of $27.39.
Hold
The current consensus among 9 polled investment analysts is to hold stock in Esperion Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/6/2019
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/5/2019
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
3/4/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/2/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
8/31/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
11/29/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/28/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/27/2021

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021Needham & Company LLCLower Price TargetStrong-Buy$150.00 ➝ $134.00High
i
2/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $30.00Low
i
2/9/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$44.00 ➝ $24.00Low
i
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$52.00 ➝ $35.00High
i
11/10/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
10/15/2020Bank of AmericaLower Price TargetBuy$55.00 ➝ $52.00Low
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageSell$35.00Low
i
8/17/2020Bank of AmericaLower Price TargetBuy$60.00 ➝ $55.00Low
i
8/11/2020Needham & Company LLCReiterated RatingBuy$158.00High
i
Rating by Chad Messer at Needham & Company LLC
8/10/2020Stifel NicolausReiterated RatingBuy$75.00High
i
Rating by Derek Archila at Stifel Nicolaus
8/10/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$83.00 ➝ $45.00High
i
Rating by Martin Auster at Credit Suisse Group AG
6/29/2020Credit Suisse GroupInitiated CoverageBuy$83.00High
i
Rating by Martin Auster at Credit Suisse Group AG
6/26/2020Stifel NicolausReiterated RatingBuy$75.00High
i
Rating by Derek Archila at Stifel Nicolaus
6/23/2020Northland SecuritiesInitiated CoverageHold$42.00High
i
Rating by Carl Byrnes at Northland Securities
6/9/2020Credit Suisse GroupReiterated RatingBuy$87.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
5/7/2020Jefferies Financial GroupLower Price TargetBuy$85.00 ➝ $70.00High
i
5/7/2020Needham & Company LLCReiterated RatingBuyHigh
i
Rating by Chad Messer at Needham & Company LLC
5/7/2020Northland SecuritiesReiterated RatingHold$42.00High
i
Rating by Carl Byrnes at Northland Securities
5/7/2020CitigroupBoost Price TargetBuy$46.00 ➝ $56.00High
i
5/6/2020Stifel NicolausReiterated RatingBuy$76.00High
i
Rating by Derek Archila at Stifel Nicolaus
4/20/2020Stifel NicolausReiterated RatingBuyLow
i
Rating by Derek Archila at Stifel Nicolaus
4/20/2020Needham & Company LLCReiterated RatingBuy$158.00Low
i
Rating by Chad Messer at Needham & Company LLC
4/16/2020Northland SecuritiesLower Price TargetMarket Perform$60.00 ➝ $42.00High
i
Rating by Carl Byrnes at Northland Securities
4/6/2020Needham & Company LLCReiterated RatingBuy$158.00High
i
Rating by Chad Messer at Needham & Company LLC
4/1/2020Bank of AmericaInitiated CoverageBuy$50.00High
i
3/31/2020Needham & Company LLCReiterated RatingBuy$158.00High
i
Rating by Chad Messer at Needham & Company LLC
3/17/2020CitigroupUpgradeNeutral ➝ BuyHigh
i
2/28/2020JPMorgan Chase & Co.Boost Price TargetNeutral$46.00 ➝ $47.00Low
i
2/27/2020CowenReiterated RatingBuy$87.00Medium
i
2/24/2020Needham & Company LLCBoost Price TargetStrong-Buy$144.00 ➝ $158.00Medium
i
2/24/2020JMP SecuritiesReiterated RatingOutperform$191.00Medium
i
2/23/2020Stifel NicolausReiterated RatingBuy$83.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
2/23/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$60.00Medium
i
Rating by Carl Byrnes at Northland Securities
2/19/2020BTIG ResearchReiterated RatingBuy$90.00Medium
i
2/14/2020CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $82.00High
i
1/31/2020Chardan CapitalReiterated RatingHold$65.00High
i
Rating by Gbola Amusa at Chardan Capital
11/6/2019CowenReiterated RatingBuyLow
i
Rating by Chris Shibutani at Cowen Inc
9/17/2019Stifel NicolausLower Price TargetBuy$112.00 ➝ $70.00Low
i
Rating by Derek Archila at Stifel Nicolaus
9/16/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$55.00 ➝ $45.00Medium
i
8/29/2019Northland SecuritiesReiterated RatingBuyHigh
i
Rating by Carl Byrnes at Northland Securities
8/8/2019Northland SecuritiesReiterated RatingBuyMedium
i
Rating by Carl Byrnes at Northland Securities
7/18/2019CowenReiterated RatingBuy$80.00Low
i
Rating by Chris Shibutani at Cowen Inc
6/14/2019Northland SecuritiesSet Price TargetBuy$65.00Medium
i
Rating by Carl Byrnes at Northland Securities
6/13/2019Stifel NicolausReiterated RatingBuyLow
i
Rating by Derek Archila at Stifel Nicolaus
6/13/2019CowenReiterated RatingBuy$85.00Medium
i
Rating by Chris Shibutani at Cowen Inc
5/29/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$50.00Medium
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
5/28/2019CitigroupSet Price TargetBuy$73.00High
i
Rating by Joel Beatty at Citigroup Inc.
5/6/2019Credit Suisse GroupBoost Price TargetOutperform$79.00 ➝ $90.00Medium
i
5/6/2019Bank of AmericaUpgradeUnderperform ➝ NeutralLow
i
5/5/2019CowenSet Price TargetBuy$94.00High
i
Rating by Chris Shibutani at Cowen Inc
4/26/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$50.00Low
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
4/2/2019Northland SecuritiesSet Price TargetBuy$65.00Low
i
Rating by Carl Byrnes at Northland Securities
3/29/2019Stifel NicolausReiterated RatingBuy$112.00Low
i
Rating by Derek Archila at Stifel Nicolaus
3/14/2019Chardan CapitalReiterated RatingHold$50.00Medium
i
3/13/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$38.00 ➝ $47.00High
i
3/1/2019Northland SecuritiesReiterated RatingBuy$65.00Low
i
Rating by Carl Byrnes at Northland Securities
1/15/2019CowenReiterated RatingBuy$94.00Low
i
Rating by Chris Shibutani at Cowen Inc
1/7/2019Needham & Company LLCBoost Price TargetStrong-Buy$94.00 ➝ $114.00Low
i
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$45.00High
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$89.00 ➝ $104.00Medium
i
10/29/2018Northland SecuritiesUpgradeMarket Perform ➝ Outperform$65.00High
i
10/26/2018CowenSet Price TargetBuy$82.00Low
i
Rating by Chris Shibutani at Cowen Inc
10/16/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$82.00High
i
9/14/2018Stifel NicolausInitiated CoverageBuy$89.00High
i
8/17/2018CitigroupUpgradeNeutral ➝ Buy$57.00 ➝ $75.00Low
i
8/6/2018CowenReiterated RatingBuy$95.00Low
i
7/20/2018Chardan CapitalUpgradeHold$32.50Low
i
7/11/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
i
5/16/2018UBS GroupSet Price TargetBuy$90.00 ➝ $75.00Low
i
Rating by Carter Gould at UBS Group AG
5/4/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$108.00 ➝ $73.00N/A
i
5/3/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$100.54 ➝ $41.00High
i
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetBuy ➝ Buy$100.00 ➝ $75.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/2/2018Bank of AmericaReiterated RatingBuy ➝ UnderperformHigh
i
4/19/2018Northland SecuritiesBoost Price TargetBuy$100.00 ➝ $121.00Low
i
3/27/2018Chardan CapitalBoost Price TargetNeutral ➝ Neutral$75.00 ➝ $100.00Low
i
3/9/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy$100.00Low
i
3/8/2018JMP SecuritiesBoost Price TargetOutperform$60.00 ➝ $153.00High
i
3/7/2018Stifel NicolausSet Price TargetBuy$105.00High
i
Rating by Alex Schwartz at Stifel Nicolaus
2/21/2018UBS GroupSet Price TargetNeutral ➝ Neutral$88.00 ➝ $90.00High
i
Rating by Carter Gould at UBS Group AG
2/21/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $65.00High
i
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$81.00 ➝ $94.00Low
i
1/22/2018CitigroupDowngradeBuy ➝ Neutral$77.00 ➝ $96.00Low
i
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$103.00Low
i
1/17/2018UBS GroupSet Price TargetBuy ➝ Buy$62.00 ➝ $88.00High
i
Rating by Carter Gould at UBS Group AG
1/15/2018Stifel NicolausSet Price TargetPositive ➝ Buy$70.00 ➝ $105.00Medium
i
Rating by Alex Schwartz at Stifel Nicolaus
1/5/2018Bank of AmericaUpgradeNeutral ➝ Buy$76.00High
i
12/14/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$72.00 ➝ $81.00Medium
i
12/6/2017Chardan CapitalBoost Price TargetNeutral$20.00 ➝ $75.00High
i
12/5/2017Chardan CapitalReiterated RatingNeutral ➝ Neutral$20.00 ➝ $75.00High
i
11/10/2017Northland SecuritiesReiterated RatingBuy$72.00N/A
i
10/4/2017Stifel NicolausReiterated RatingBuy$70.00Medium
i
10/4/2017Northland SecuritiesReiterated RatingBuy$72.00Medium
i
9/7/2017CowenInitiated CoverageOutperform$64.00Low
i
8/29/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$72.00Medium
i
8/21/2017Jefferies Financial GroupReiterated RatingBuy$85.00Low
i
8/11/2017Bank of AmericaReiterated RatingNeutral ➝ Neutral$60.00Medium
i
8/10/2017Stifel NicolausReiterated RatingBuy$60.00 ➝ $70.00High
i
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$48.00 ➝ $64.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
8/8/2017Jefferies Financial GroupUpgradeHold ➝ Buy$85.00 ➝ $55.00Low
i
8/8/2017Needham & Company LLCBoost Price TargetBuy ➝ Positive$58.00 ➝ $72.00High
i
Rating by Chad Messer at Needham & Company LLC
7/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$55.00Low
i
6/27/2017UBS GroupReiterated RatingBuy$52.00 ➝ $57.00N/A
i
6/26/2017Stifel NicolausReiterated RatingBuy ➝ Buy$45.00 ➝ $60.00Low
i
6/23/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$48.00High
i
6/22/2017CitigroupReiterated RatingBuyHigh
i
Rating by Joel Beatty at Citigroup Inc.
3/29/2017UBS GroupUpgradeNeutral ➝ Buy$23.00 ➝ $52.00N/A
i
3/21/2017CitigroupBoost Price Target$77.00High
i
Rating by Joel Beatty at Citigroup Inc.
3/21/2017JPMorgan Chase & Co.Boost Price Target$22.00 ➝ $50.00High
i
3/20/2017JPMorgan Chase & Co.Reiterated RatingHold$22.00 ➝ $50.00Medium
i
Rating by Jessica Fye at JPMorgan Chase & Co.
3/20/2017CitigroupSet Price TargetBuy$39.00Medium
i
Rating by Joel Beatty at Citigroup Inc.
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00High
i
3/20/2017Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $58.00High
i
Rating by Chad Messer at Needham & Company LLC
3/20/2017Credit Suisse GroupUpgradeUnderperform ➝ Neutral$29.00High
i
3/18/2017Needham & Company LLCSet Price TargetBuy$25.00High
i
Rating by Chad Messer at Needham & Company LLC
3/13/2017CitigroupSet Price TargetBuy$39.00Low
i
Rating by Joel Beatty at Citigroup Inc.
2/28/2017CitigroupUpgradeNeutral ➝ Buy$14.00 ➝ $39.00N/A
i
Rating by Joel Beatty at Citigroup Inc.
2/23/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$20.00 ➝ $30.00N/A
i
2/16/2017UBS GroupBoost Price TargetNeutral$11.00 ➝ $23.00N/A
i
2/7/2017Royal Bank of CanadaSet Price TargetHold$20.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
2/4/2017Needham & Company LLCSet Price TargetBuy$25.00N/A
i
Rating by Chad Messer at Needham & Company LLC
1/10/2017Needham & Company LLCReiterated RatingBuy$25.00N/A
i
1/3/2017Royal Bank of CanadaReiterated RatingHold$15.00N/A
i
12/20/2016Credit Suisse GroupReiterated RatingSell$12.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
11/14/2016CitigroupDowngradeBuy ➝ NeutralN/A
i
Rating by Joel Beatty at Citigroup Inc.
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Jason Butler at JMP Securities
10/15/2016Stifel NicolausReiterated RatingBuy$64.00 ➝ $30.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
10/14/2016Credit Suisse GroupBoost Price TargetUnderperform$10.00 ➝ $14.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
10/13/2016Chardan CapitalSet Price TargetHold$13.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
9/22/2016Stifel NicolausReiterated RatingBuy$64.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
8/31/2016BarclaysSet Price TargetHold$13.00N/A
i
Rating by jonathan eckard at Barclays PLC
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$15.00N/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
7/6/2016Credit Suisse GroupReiterated RatingSell$10.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
7/5/2016WallachBeth CapitalDowngradeBuy ➝ Hold$35.00N/A
i
7/5/2016UBS GroupDowngradeBuy ➝ Neutral$69.00 ➝ $11.00N/A
i
6/30/2016Stifel NicolausDowngradeNeutral ➝ Underperform$23.00 ➝ $10.00N/A
i
6/29/2016Chardan CapitalReiterated RatingHold$13.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
6/29/2016Needham & Company LLCReiterated RatingBuy$77.00 ➝ $25.00N/A
i
6/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$28.00 ➝ $13.00N/A
i
6/29/2016CitigroupReiterated RatingBuy$36.00 ➝ $22.00N/A
i
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 ➝ $27.00N/A
i
6/29/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$30.00 ➝ $15.00N/A
i
6/29/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$50.00 ➝ $15.00N/A
i
6/29/2016Credit Suisse GroupDowngradeNeutral ➝ Underperform$23.00 ➝ $10.00N/A
i
6/16/2016JMP SecuritiesReiterated RatingBuy$67.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$113.00 ➝ $67.00N/A
i
Rating by Jason Butler at JMP Securities
2/28/2016Chardan CapitalReiterated RatingHoldN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
(Data available from 2/27/2016 forward)
Esperion Therapeutics logo
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $27.39
$26.23
$28.24

50 Day Range

MA: $29.93
$25.12
$36.89

52 Week Range

Now: $27.39
$23.90
$56.85

Volume

699,140 shs

Average Volume

979,607 shs

Market Capitalization

$763.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Bank of America Co., Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Northland Securities, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $52.89, suggesting a possible upside of 93.1%. Needham & Company LLC has the highest price target set, predicting ESPR will reach $134.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $24.00 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 2 sell ratings, 3 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com.